Macro Strategist, Saxo Capital Markets

Kay Van-Petersen

Macro Strategist

Saxo Capital Markets

Thematic (Sector/Industry)

<ul><li>Post SNB surprise announcement yesterday - after leading the market on as recently as a few weeks ago on – the term “Never trust a Swiss central banker” will soon become mainstream.&nbsp; </li><li>In this piece, KVP takes a snap shot of what happened, the significance &amp; potential ways to look to play things going forward. </li></ul>

Post SNB surprise announcement yesterday - after leading the market on as recently as a few weeks ago on – the term “Never trust a Swiss central banker” will soon become mainstream.&nbsp; In this piece, KVP takes a snap shot of what happened, the significance &amp; potential ways to look to play things going forward. 

Index Rebalance and Special Situations Coverage, Quiddity Advisors

Anjana Amarasuriya

Index Rebalance and Special Situations Coverage

Quiddity Advisors

Pan-Asia Catalysts/Events

Index Rebalance

<ul>
<li>The Spider Select Sector indices are a family of 11 sector-specific indices derived from the SP 500 index based on GICS (Global Industry Classification Standard) classifications.</li>
<li>In this insight, we have presented our expectations for capping flows and SP 500-driven sector tracking fund rebalance flows for the upcoming quarterly review in March 2026.</li>
<li>We expect one-way flow of ~US$7bn in March 2026 for the Select Sector indices in total.</li>
</ul>


The Spider Select Sector indices are a family of 11 sector-specific indices derived from the SP 500 index based on GICS (Global Industry Classification Standard) classifications.
In this insight, we have presented our expectations for capping flows and SP 500-driven sector tracking fund rebalance flows for the upcoming quarterly review in March 2026.
We expect one-way flow of ~US$7bn in March 2026 for the Select Sector indices in total.


Quiddity Leaderboard SP Select Sector Mar26 Rebal: One-Way US$7bn Flow Expected

Independent research on the U.S. markets, Baptista Research

Baptista Research

Independent research on the U.S. markets

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

Equity Bottom-Up

Davita Healthcare Partners / Equity Bottom-Up

<ul><li>DaVita Inc., a leading provider of kidney dialysis services, reported its second-quarter 2025 earnings.</li><li>The company highlighted a relatively stable financial performance but continues to face challenges in treatment volumes and missed treatments, partially attributable to a cyber incident earlier in the year.</li><li>On the positive side, DaVita demonstrated an ability to manage costs effectively, which helped maintain its guidance for adjusted operating income and earnings per share for the full year.</li></ul>

DaVita Inc., a leading provider of kidney dialysis services, reported its second-quarter 2025 earnings.The company highlighted a relatively stable financial performance but continues to face challenges in treatment volumes and missed treatments, partially attributable to a cyber incident earlier in the year.On the positive side, DaVita demonstrated an ability to manage costs effectively, which helped maintain its guidance for adjusted operating income and earnings per share for the full year.

DaVita Inc. Reels From Cyberattack — Can It Restore Treatment Volumes & Revenue Growth?

<ul><li>DaVita Inc. (DVA) has recently disclosed its financial results for the first quarter of 2025.</li><li>The company faced significant challenges, most notably a cybersecurity incident, which disrupted operations.</li><li>Despite these setbacks, DaVita succeeded in maintaining its patient care levels and mitigating the impact on its core services.</li></ul>

DaVita Inc. (DVA) has recently disclosed its financial results for the first quarter of 2025.The company faced significant challenges, most notably a cybersecurity incident, which disrupted operations.Despite these setbacks, DaVita succeeded in maintaining its patient care levels and mitigating the impact on its core services.

DaVita Incorporated: Phosphate Binders Integration into Dialysis Benefit As A Pivotal Growth Lever!

<ul><li>DaVita ended 2024 strongly, with adjusted operating income of $1.98 billion and adjusted earnings per share (EPS) growing by 26% year-over-year, reaching $9.68.</li><li>However, challenges such as the Change Healthcare outage and supply chain disruptions due to Hurricane Helene impacted performance.</li><li>These issues contributed to a $6 million negative impact on operating income in the fourth quarter.</li></ul>

DaVita ended 2024 strongly, with adjusted operating income of $1.98 billion and adjusted earnings per share (EPS) growing by 26% year-over-year, reaching $9.68.However, challenges such as the Change Healthcare outage and supply chain disruptions due to Hurricane Helene impacted performance.These issues contributed to a $6 million negative impact on operating income in the fourth quarter.

DaVita Inc.: Is Their Expectation Regarding Revenue Per Treatment Growth Reasonable?

United States

DaVita Inc. provides a variety of health care services. The Company provides kidney dialysis services for patients suffering from chronic kidney failure. DaVita serves patients worldwide.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

DaVita (DVA UN)

Never Trust A Swiss Central Banker

Post SNB surprise announcement yesterday - after leading the market on as recently as a few weeks ago on – the term “Never trust a Swiss central...

Kay Van-Petersen

Quiddity Leaderboard SP Select Sector Mar26 Rebal: One-Way US$7bn Flow Expected

This insight shows the breakdown of flows expected for the S&P Select Sector indices at the March rebalance. We see US$7bn a side on top of the...

Anjana Amarasuriya

DaVita Inc. Reels From Cyberattack — Can It Restore Treatment Volumes & Revenue Growth?

DaVita Inc., a leading provider of kidney dialysis services, reported its second-quarter 2025 earnings. The company highlighted a relatively...

Baptista Research

DaVita Incorporated: Phosphate Binders Integration into Dialysis Benefit As A Pivotal Growth Lever!

DaVita Inc. (DVA) has recently disclosed its financial results for the first quarter of 2025. The company faced significant challenges, most...

Baptista Research

DaVita Inc.: Is Their Expectation Regarding Revenue Per Treatment Growth Reasonable?

DaVita ended 2024 strongly, with adjusted operating income of $1.98 billion and adjusted earnings per share (EPS) growing by 26% year-over-year,...

Baptista Research

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)